TRINETRA › Sectors › Healthcare
Indegene Limited (INDGN) — share price, P/E and fundamentals
Indegene Limited (NSE: INDGN) closed at ₹586.80 on 30 Oct 2026, +8.1% over one year, against a 52-week range of ₹414.00 – ₹627.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 29 Oct 2026) it reported revenue of ₹1,122 cr and net profit of ₹112 cr, a 10.0% net margin; revenue grew 39.6% and profit grew 10.7% year on year.
On four consecutive filed quarters its trailing P/E is 34.3; since 28 Apr 2025 its own P/E has ranged from 23.1 to 36.7 (median 31.7), and today's reading is higher than 84% of those 373 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 13.4%, ROCE 17.3%, debt-to-equity 0.00, Piotroski F-score 5 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 24% of 63 sector peers; PBT margin higher than 25% of 63 sector peers; ROE higher than 46% of 63 sector peers.
Key figures
| Last close | ₹586.80 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -1.2% / +19.3% / +8.1% |
| 52-week low – high | ₹414.00 – ₹627.00 |
| Market capitalisation | ₹14,113 cr |
| Trailing P/E | 34.3 |
| Price / book | 4.20 |
| EV / EBITDA | 19.0 |
| Earnings yield | 2.9% |
| TTM EPS | ₹17.09 |
| TTM net profit | ₹411 cr |
| Quarter revenue | ₹1,122 cr |
| Quarter net profit | ₹112 cr |
| Net margin | 10.0% |
| Revenue growth (YoY) | +39.6% |
| Profit growth (YoY) | +10.7% |
| Return on equity | 13.4% |
| ROCE | 17.3% |
| Debt / equity | 0.00 |
| Current ratio | 2.47 |
| Free cash flow | ₹-38 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹20.4 cr |
Against Healthcare peers
| Metric | INDGN | Peer median | Percentile |
|---|---|---|---|
| Net margin | 10.01 | 12.89 | 24 |
| PBT margin | 13.13 | 17.68 | 25 |
| ROE | 13.38 | 13.87 | 46 |
| ROCE | 17.26 | 16.59 | 51 |
| Debt / equity | 0.00 | 0.11 | 12 |
| FCF margin | -1.76 | 2.08 | 36 |
| Cash conversion | -0.06 | 1.25 | 3 |
| Trailing P/E | 34.33 | 43.26 | 25 |
Questions
What is the P/E ratio of Indegene Limited?
Indegene Limited's trailing P/E is 34.3, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 28 Apr 2025 its P/E has ranged 23.1–36.7.
What were Indegene Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Indegene Limited reported revenue of ₹1,122 cr and net profit of ₹112 cr (consolidated), filed with the exchange on 29 Oct 2026.
What is Indegene Limited's ROE?
Return on equity is 13.4% based on the balance sheet dated 30 Sept 2026.
Does Indegene Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.
What is INDGN's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, INDGN traded between ₹414.00 and ₹627.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.